Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Oct;78(8):1035–1042. doi: 10.1038/bjc.1998.624

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.

U Zangemeister-Wittke 1, T Schenker 1, G H Luedke 1, R A Stahel 1
PMCID: PMC2063150  PMID: 9792147

Abstract

Expression of Bcl-2 is life-sustaining for small-cell lung cancer cells and associated with drug resistance. In the present study, the interactions between the bcl-2 antisense oligodeoxynucleotide 2009 and the chemotherapeutic agents etoposide, doxorubicin and cisplatin were investigated on small-cell lung cancer cell lines to search for synergistic combinations. The cell lines NCI-H69, SW2 and NCI-H82 express high, intermediate-high and low basal levels of Bcl-2, respectively, which are inversely correlated with the sensitivities of the cell lines to treatment with oligodeoxynucleotide 2009 and the chemotherapeutic agents alone. Moreover, differences were found in the responsiveness of the cell lines to treatment with combinations of oligodeoxynucleotide 2009 and the chemotherapeutic agents. In the cell lines NCI-H69 and SW2, all combinations resulted in synergistic cytotoxicity. In NCI-H69 cells, maximum synergy with a combination index of 0.2 was achieved with the combination of oligodeoxynucleotide 2009 and etoposide. In SW2 cells, the combination of oligodeoxynucleotide 2009 and doxorubicin was the most effective (combination index = 0.5). In the cell line NCI-H82, which expresses a low basal level of Bcl-2, most of the combinations were slightly antagonistic. Our data suggest the use of oligodeoxynucleotide 2009 in combination with chemotherapy for the treatment of small-cell lung cancer that overexpresses Bcl-2.

Full text

PDF
1035

Images in this article

1037Figure 1
on p.1037

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Ezra J. M., Kornstein M. J., Grimes M. M., Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol. 1994 Nov;145(5):1036–1040. [PMC free article] [PubMed] [Google Scholar]
  2. Bennett C. F., Chiang M. Y., Chan H., Shoemaker J. E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1992 Jun;41(6):1023–1033. [PubMed] [Google Scholar]
  3. Campos L., Rouault J. P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J. P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993 Jun 1;81(11):3091–3096. [PubMed] [Google Scholar]
  4. Cotter T. G., Lennon S. V., Glynn J. M., Green D. R. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis. Cancer Res. 1992 Feb 15;52(4):997–1005. [PubMed] [Google Scholar]
  5. Cucco C., Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res. 1996 Oct 1;56(19):4332–4337. [PubMed] [Google Scholar]
  6. Del Bufalo D., Cucco C., Leonetti C., Citro G., D'Agnano I., Benassi M., Geiser T., Zon G., Calabretta B., Zupi G. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer. 1996 Aug;74(3):387–393. doi: 10.1038/bjc.1996.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dole M., Nuñez G., Merchant A. K., Maybaum J., Rode C. K., Bloch C. A., Castle V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994 Jun 15;54(12):3253–3259. [PubMed] [Google Scholar]
  8. Dosaka-Akita H., Akie K., Hiroumi H., Kinoshita I., Kawakami Y., Murakami A. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res. 1995 Apr 1;55(7):1559–1564. [PubMed] [Google Scholar]
  9. Doyle L. A. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol. 1993 Aug;20(4):326–337. [PubMed] [Google Scholar]
  10. Gonzalez Manzano R., Versanvoort C., Wright K., Twentyman P. R. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer. 1996 Nov;32A(12):2136–2141. doi: 10.1016/s0959-8049(96)00263-8. [DOI] [PubMed] [Google Scholar]
  11. Greco W. R., Bravo G., Parsons J. C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995 Jun;47(2):331–385. [PubMed] [Google Scholar]
  12. Ho P. T., Parkinson D. R. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol. 1997 Apr;24(2):187–202. [PubMed] [Google Scholar]
  13. Kamesaki S., Kamesaki H., Jorgensen T. J., Tanizawa A., Pommier Y., Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 1993 Sep 15;53(18):4251–4256. [PubMed] [Google Scholar]
  14. Kaufmann S. H., Peereboom D., Buckwalter C. A., Svingen P. A., Grochow L. B., Donehower R. C., Rowinsky E. K. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996 Jun 5;88(11):734–741. doi: 10.1093/jnci/88.11.734. [DOI] [PubMed] [Google Scholar]
  15. Kitada S., Takayama S., De Riel K., Tanaka S., Reed J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev. 1994 Summer;4(2):71–79. doi: 10.1089/ard.1994.4.71. [DOI] [PubMed] [Google Scholar]
  16. Lai S. L., Goldstein L. J., Gottesman M. M., Pastan I., Tsai C. M., Johnson B. E., Mulshine J. L., Ihde D. C., Kayser K., Gazdar A. F. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989 Aug 2;81(15):1144–1150. doi: 10.1093/jnci/81.15.1144. [DOI] [PubMed] [Google Scholar]
  17. Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993 Jan 1;81(1):151–157. [PubMed] [Google Scholar]
  18. Miyashita T., Reed J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992 Oct 1;52(19):5407–5411. [PubMed] [Google Scholar]
  19. Monia B. P., Sasmor H., Johnston J. F., Freier S. M., Lesnik E. A., Muller M., Geiger T., Altmann K. H., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15481–15484. doi: 10.1073/pnas.93.26.15481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ohmori T., Podack E. R., Nishio K., Takahashi M., Miyahara Y., Takeda Y., Kubota N., Funayama Y., Ogasawara H., Ohira T. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun. 1993 Apr 15;192(1):30–36. doi: 10.1006/bbrc.1993.1377. [DOI] [PubMed] [Google Scholar]
  21. Photiou A., Shah P., Leong L. K., Moss J., Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer. 1997 Mar;33(3):463–470. doi: 10.1016/s0959-8049(97)89023-5. [DOI] [PubMed] [Google Scholar]
  22. Reeve J. G., Xiong J., Morgan J., Bleehen N. M. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer. 1996 May;73(10):1193–1200. doi: 10.1038/bjc.1996.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Skorski T., Nieborowska-Skorska M., Wlodarski P., Perrotti D., Hoser G., Kawiak J., Majewski M., Christensen L., Iozzo R. V., Calabretta B. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst. 1997 Jan 15;89(2):124–133. doi: 10.1093/jnci/89.2.124. [DOI] [PubMed] [Google Scholar]
  24. Souhami R. L., Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer. 1990 Apr;61(4):584–589. doi: 10.1038/bjc.1990.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004–1012. doi: 10.1126/science.8351515. [DOI] [PubMed] [Google Scholar]
  26. Stein C. A., Krieg A. M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67–69. doi: 10.1089/ard.1994.4.67. [DOI] [PubMed] [Google Scholar]
  27. Strasser A., Harris A. W., Jacks T., Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 1994 Oct 21;79(2):329–339. doi: 10.1016/0092-8674(94)90201-1. [DOI] [PubMed] [Google Scholar]
  28. Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguarnera L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991 Aug 2;253(5019):562–565. doi: 10.1126/science.1857987. [DOI] [PubMed] [Google Scholar]
  29. Versantvoort C. H., Rhodes T., Twentyman P. R. Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer. 1996 Dec;74(12):1949–1954. doi: 10.1038/bjc.1996.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Webb A., Cunningham D., Cotter F., Clarke P. A., di Stefano F., Ross P., Corbo M., Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997 Apr 19;349(9059):1137–1141. doi: 10.1016/s0140-6736(96)11103-x. [DOI] [PubMed] [Google Scholar]
  31. Ziegler A., Luedke G. H., Fabbro D., Altmann K. H., Stahel R. A., Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 1997 Jul 16;89(14):1027–1036. doi: 10.1093/jnci/89.14.1027. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES